Eurofarma Innovation and Growth Strategy slide image

Eurofarma Innovation and Growth Strategy

6 eurofarma COMPLETE PORTFOLIO Growth Profile Institutional 1H22 Consolidated Net Sales1 R$3.9 bi (+12.5% vs. 1H21) Prescription 63,4% Generic 16,4% Hospitals 7,7% Oncologic 2,3% Public Sector 5,1% Others2 23 5,1% Prescription #1 9.6% market share (Close-up) #2 6.2% market share Generic (IQVIA) market share #2 14.2% (IQVIA) Hospitals #7 3.8% market share #1 Oncologic (IQVIA) #11 1.6% market share #32 (IQVIA) Public Sector (Bids) market share #19 1.5% (QVIA) Latin America #3 3.4% market share (IQVIA) Regional-based pharma4 (IQVIA) #2 Brazil 5 #3 5.9% market share (IQVIA) 1- Eurofarma Corp (Eurofarma+Momenta+Supera) / 2- OTC + Outsourcing Services + Exports / 3- Excluding multinational pharma companies not based in Brazil / 4- Excluding multinational pharma companies not based in Latin America / 5- Retail Reais PPP / NRA Reais PP (Total Pharmaceutical Market, excluding Covid-19 vaccines).
View entire presentation